

Listing on the OTCQB market to facilitate access to US investors

- Trading on OTCQB to commence on 16 April 2025 under ticker code ECHQF
- OTCQB is a specialist investment platform for developing US and international companies and is recognised as an Established Public Market by the US Securities Exchange Commission (“SEC”)
- Platform facilitates direct investment with US capital markets, including real-time access for US retail and institutional investors, with trading in USD
- In 2024 total dollar trading across all OTC Markets reached ~US\$478.7Bn, up from US\$383Bn in the prior year
- Growth in trading volumes was supported by international securities trading which totalled US\$415Bn, up US\$92Bn from the previous year
- Listing follows positive US investor engagement, including a recent US roadshow which highlighted strong interest in Echo IQ’s commercialisation objectives
- Aligns with EIQ’s stated strategy in the US, which is focused on the uptake of EchoSolv technology to assist in the early detection of structural heart disease
- Recent commercialisation initiatives led by major integration partnership with ScImage for the deployment of EchoSolv AS across 36 US hospitals affiliated with the MedAxiom network
- EIQ’s status as an ASX-listed company qualifies it for a key exemption under US listing regulations – allows for reduced compliance costs while expanding US investor engagement

Sydney: AI and Medical Technology company Echo IQ (“the Company” or “Echo IQ”) (ASX: EIQ) is pleased to advise it has been approved to trade on the OTCQB Venture Market (“OTCQB”) in the United States. Trading will commence at market open on 16 April 2025 (New York time) under the code ECHQF (www.otcmarkets.com/stock/ECHQF/profile).

The listing follows a recent US roadshow, undertaken by Echo IQ CEO, Mr Dustin Haines, where strong interest in the Company was observed from a range of private investors and institutions. The listing of the Company’s shares on the OTCQB will provide Echo IQ shareholders with potential access to new investor groups, as well as increased liquidity to support the ongoing commercialisation of the Company’s innovative EchoSolv technology.

The OTCQB listing will allow US investors to trade EIQ’s ordinary shares in US dollars during US market hours. It also provides Echo IQ with a platform to forge strong partnerships in US capital markets through targeted research, data analysis, media and investor relations and a direct channel for US investors to obtain simplified access to the same information and disclosures as Australian investors.

The OTC market has grown in popularity recently. In 2024, the total dollar volume traded across all OTC Markets (including OTCQX, OTCQB, and Pink) reached approximately US\$478.7Bn, marking a significant increase from the previous year’s US\$383Bn. This growth was particularly strong in international securities trading, which reached US\$415Bn, up US\$92Bn from the previous year¹.

Operationally, Echo IQ has continued to build strong momentum with its US commercialisation strategy, highlighted by a recent integration partnership which will facilitate the deployment of EchoSolv AS on the ScImage platform across up to 36 hospitals within the MedAxiom network - an American College of Cardiology company that provides organisational performance solutions for cardiology specialists.

Echo IQ will continue to provide disclosures and announcements to the Australian Securities Exchange (“ASX”) in line with Market Operation Rules and Listing Rule requirements. Information provided by the Company to the ASX will also now be uploaded onto the OTC Markets platform for US investors. No new ordinary shares have been issued in connection with the OTCQB listing.

Chief Executive Officer, Mr Dustin Haines said: *“The listing on the OTCQB is anticipated to considerably improve access for US-based investors wishing to become more involved in Echo IQ. This listing comes at a pivotal time in the Company’s commercialisation journey and will further support our ongoing progress in the US market with key hospital groups seeking exposure to EchoSolv AS, alongside planned trials for our innovative heart failure screening tool, EchoSolv HF.”*

“The Company’s OTCQB listing follows a successful round of investor meetings in New York, which clearly demonstrated the appetite for Echo IQ’s medical technology solution with a range of professional investors and institutional groups. We look forward to engaging with US investors more aggressively alongside the advancement of our US-based commercialisation strategy, to complement the strong support we’ve received from Australian investors.”

- ENDS -

Authorised for release by the Board of Directors of Echo IQ Limited.

Investor Enquiries:

Andrew Grover, Executive Chair
Andrew.grover@echoiq.ai / investor@echoiq.ai

Henry Jordan, Six Degrees Investor Relations
Henry.jordan@sdir.com.au / +61 (0) 431 271 538

ABOUT ECHO IQ

Echo IQ uses AI-driven technology and proprietary software to improve decision making in Cardiology. The company is based in Sydney, Australia.

¹ https://www.globenewswire.com/news-release/2025/01/28/3016235/0/en/OTC-Markets-Group-Reports-478-7-Billion-in-Total-Dollar-Volume-Traded-for-2024-Marking-Significant-Year-Over-Year-Growth.html?utm_source=chatgpt.com